AVITA Medical Inc (RCEL) Stock Analysis
Verdict: WATCH (do not buy)
Elite gross margins and insider buying battle a collapsing balance sheet and chronic earnings misses—dilution is the primary gatekeeper.
Investment score: 48/100
Analysis as of
Is AVITA Medical Inc stock worth reviewing? AI model thesis
AVITA Medical (RCEL) presents a classic biotech dichotomy: a validated product with 81% gross margins vs. a balance sheet in terminal decline. With only $10.2M in cash against a $31M annual burn and negative total equity, the model anticipates a highly dilutive financing event. Insider buying provides a floor, but four straight earnings misses suggest operational execution is not yet meeting lofty analyst expectations ($8.00 target).
7-factor investment score
- Valuation: 40/100 (weight 20%)
- Financial Health: 30/100 (weight 15%)
- Technical Momentum: 45/100 (weight 15%)
- Earnings Quality: 20/100 (weight 15%)
- Insider Sentiment: 90/100 (weight 10%)
- Analyst Consensus: 85/100 (weight 10%)
- Risk-Adjusted Return: 40/100 (weight 15%)
AVITA Medical Inc opportunities and risks
What speaks for RCEL
- Elite Product Economics
What speaks against RCEL
- Imminent Solvency Crisis / Dilution Risk
Peers and competitors
| Ticker | P/E | P/S | EV/EBITDA | Gross margin | Net margin | FCF yield |
|---|---|---|---|---|---|---|
| RCEL | n/a | 1.5x | n/a | 81.4% | -62.7% | -29.3% |
| AGEN | 2.0x | 1.1x | 4.6x | 52.1% | 52.2% | -63.2% |
| GNLX | n/a | 14365.0x | n/a | -3550.0% | -397225.0% | -24.3% |
| BDTX | n/a | 0.0x | n/a | 0.0% | 0.0% | -25.0% |
| CRDF | n/a | 254.6x | n/a | -2147.8% | -8527.2% | -28.0% |
| CYPH | n/a | 0.0x | n/a | 0.0% | 0.0% | -61.4% |
| Peer median | n/a | 1.1x | n/a | 0.0% | 0.0% | -28.0% |
Frequently asked questions about AVITA Medical Inc (RCEL)
Is RCEL stock a good investment?
The cached TradeMates AI model rates AVITA Medical Inc as WATCH (do not buy) with an investment score of 48/100. AVITA Medical (RCEL) presents a classic biotech dichotomy: a validated product with 81% gross margins vs. a balance sheet in terminal decline. With only $10.2M in cash against a $31M annual burn and negative total equity, the model anticipates a highly dilutive financing event. Insider buying provides a floor, but four straight earnings misses suggest operational execution is not yet meeting lofty analyst expectations ($8.00 target). This is algorithmic model output, not personal investment advice.
Is RCEL stock a buy?
The TradeMates model verdict for RCEL is WATCH (do not buy) with an investment score of 48/100. Treat this as a model signal to review, not a personal buy recommendation.